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Abstract
Objective: To investigate whether early intervention with recombinant human growth hormone
(hGH) after hip fracture improves functional recovery and long-term outcome.
Subjects and methods: Functional recovery after hip fracture is often incomplete. The catabolic
situation that develops after the hip fracture accident, and a state of malnutrition either pre-existing
or developing after surgery, are main contributing factors for the poor clinical outcome. hGH has been
used to promote anabolism in a variety of clinical catabolic situations. The study design was
randomized, double-blind and placebo-controlled. A total of 111 patients older than 60 years with
an accidental hip fracture (mean age 78:5 ^ 9:1 (S.D.) years) were randomized to receive either hGH
(20 mg/kg per day) or placebo for a period of 6 weeks, starting within 24 h after the hip fracture
accident. Thereafter patients were followed up for an additional period of 18 weeks. Efficacy was
assessed by comparing the changes in the Barthel Index score of activities of daily living and in a
patient's living situation between the hGH- and the placebo-treated subjects.
Results: Eighty-five (78.5%) patients completed the first 8 weeks of the study and 76 (68.5%) the
entire study period of 24 weeks. When split according to age, a trend was found that for patients older
than 75 years the changes in Barthel Index score from baseline were less in the hGH group than in
the placebo group 218:6 ^ 18 vs 228:1 ^ 26 at 6 weeks after surgery P , 0:075: There was an
overall trend to a higher rate of return to the pre-fracture independent living situation in the hGH
group than in the placebo group. Analysis by age revealed a significantly higher proportion of hGH-
than placebo-treated patients returning to the pre-fracture living situation for subjects older than 75
years (93.8 vs 75.0%, P  0:034: hGH treatment increased IGF-I values to levels in the range of
those of normal subjects of 50±60 years of age.
Conclusions: A 6 week treatment with hGH (20 mg/kg per day) of otherwise healthy patients after an
accidental hip fracture may be of benefit if given to subjects older than 75 years of age. The rate of
return to the pre-fracture living situation in subjects of this age treated with hGH was significantly
increased when compared with the placebo-treated group. The treatment intervention was well
tolerated and no safety issues were recorded.
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Introduction
Hip fractures are a large and increasing health
problem, with estimates that about 1.7 million
occurred world-wide in 1990 (1, 2). Recent reports
document an incidence of 96.1/100 000 (Europe) to
80/100 000 (United States) (3±6). Cooper and co-
workers applied available incidence rates from various
parts of the world to projected populations in 1990,
2025 and 2050 (7). They calculated that the number
of hip fractures occurring in the world every year will
rise from 1.66 million in 1990 to 6.26 millions by the
year 2050.
Functional recovery after fracture is often incomplete
and many patients cannot resume their previous living
habits (8, 9). Rates of institutional care are high and
remain higher than average as the individual grows older
(10±12). Reasons for the poor outcome of hip fracture
patients include their general catabolic state, loss of muscle
tissue and a state of malnutrition either pre-existing or
developing after surgery (12, 13). Nutritional support
alone has been shown to have limited effect in controlling
the rate of catabolism in acute and chronic illnesses (14,
15). Recombinant human growth hormone (hGH) has
been shown to promote nitrogen retention and to preserve
lean body mass in humans (16±19), and has been used as
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a pharmacological agent to promote anabolism in a variety
of disorders associated with increased catabolism (20±22).
Therefore it might be possible to keep hip fracture patients
in an anabolic state by administration of hGH from the
early phase after the fracture until recovery after opera-
tion, thus improving short-term remobilization and long-
term clinical outcome. The present study was designed to
investigate whether an early therapeutic intervention with




Patients were male or female, older than 60 years of age,
with an accidental hip fracture, defined as requiring
surgery with open reduction and internal fixation (to
exclude hemiarthroplasty, which was not considered
desirable for the purpose of the study). Patients were
required to have a pre-fracture Modified Barthel Index
score $85 (see below). Patients with overt congestive
heart failure, hypertension, hepatic or kidney insufficiency,
active cancer disease, neuromuscular condition, rheuma-
toid arthritis or diabetes were excluded from the study.
Study design
The study used a double-blind, placebo-controlled
design, conducted by 12 investigators in two countries
(The Netherlands and Germany). The study was
conducted in accordance with EC Good Clinical
Practice Guidelines and in compliance with local
institutional review board/ethics committee regula-
tions. Informed consent was obtained before enrolment
into the study. Subjects fulfilling the entry criteria were
randomized to either hGH (Humatrope; Eli Lilly and
Company, Indianapolis, USA) or placebo. Treatment
was started within 24 h of hospital admission. Patients
were treated for a period of 6 weeks, starting at a dose
of 10 mg/kg per day and increasing to 20 mg/kg per
day within the first 6 days. After 6 weeks the dosage
was decreased during a period of 6 days, and therapy
then stopped. To assess the long-term outcome, blinded
follow-up of the patients was continued for an
additional 18 weeks. Thus, the total study period was
24 weeks (6 months).
To ensure adequate protein repletion after the hip
fracture accident and the surgical intervention (15),
nutritional intake was optimized as far as possible by
giving patients at least three bottles of enriched protein
beverage (each bottle containing 150 kcal, 6.5 g fat, 5 g
protein and 17.9 g carbohydrates) when their food intake
was less than 1500 kcal per day. Clinical assessments
were performed on hospital admission (within 24 h) and
then at 2, 4, 6, 8, 12 and 24 weeks after surgery.
Methods
Functional status after hGH or placebo and rates of return
to pre-fracture living situation were the essential features
to be assessed. To assess the functional status of the patient
(e.g. bathing, toilet, dressing, transfers, climbing stairs)
the Modified Barthel Index of activities of daily living
(ADL) was chosen (23, 24). The index consists of ten
individual items with the values assigned to each item
based upon the amount of assistance required to perform
the task. The total score ranges from 0 to100, where 100
indicates the patient is fully independent in his ADLs and
zero that the patient is totally dependent.
Housing and living situation was documented at
admission (to determine pre-fracture living status)
upon discharge from hospital, and at subsequent
follow-up visits after discharge. Patients were classified
into three groups as follows: 1. house/flat, old people's
flat, service flat; 2. sheltered accommodation, retire-
ment home, nursing/convalescent home; 3. hospital.
Group 1 was defined as in an independent and group 2
as in a dependent living situation. The separation
between independent and dependent living situations
was made at the level of sheltered accommodation as in
the countries in which the study was performed (The
Netherlands and Germany) adjustments which affect
mobility items (e.g. handrail/grabrail in bathroom) are
primarily introduced at this level of care.
Hormone assays Serum insulin-like growth factor-I
(IGF-I) and IGF-binding protein (IGFBP)-1 and -3 levels
were measured by a central laboratory at each visit.
Investigators ensured that appropriate medical care
was maintained throughout the study and after the
trial and were also responsible for monitoring the safety
of patients and for reporting immediately any adverse
event or any event that seemed unusual. Safety of hGH-
and placebo-treated patients was assessed through
laboratory data, vital signs, rates of discontinuation
and treatment-emergent adverse events. Treatment-
emergent adverse events were those which occurred for
the first time during active therapy or events present at
baseline and which became more severe during the
active treatment phase.
Statistical analysis
Published data on the use of the Barthel Index to assess hip
fractures outcome were used for sample size calculations
(24). The study was powered to detect a 12 point difference
in the Barthel Index between treatment groups after 8
weeks at a significance level of 0.05.
The null hypothesis that no difference existed in clinical
recovery between the two treatment groups was analyzed
in several ways using different techniques. The change in
ADL score from baseline to endpoint was used to determine
a patient's quality of recovery toward their pre-fracture
status. This was tested using ANOVA in SAS PROC GLM.
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Analyses were performed on the original data and on the
rank-transformed data derived using SAS PROC RANK.
Analysis of effects of hGH treatment on GH-dependent
parameters was done using methods identical to those
given for the ADLs. Post-hoc exploratory analyses to look
into the pattern of changes in living situation were
performed using categorical repeated measures technique
with weighted least squares in SAS PROC CATMOD (25).
Analysis was performed firstly with a full model consisting
of treatment, visit, and the treatment-by-visit interaction.
If the interaction was not significant P . 0:10 then it
was removed from the model and the main effects model
remained. Incidence rates for each adverse event were




The baseline characteristics of the patients are presented
in Table 1. A total of 111 patients (55 hGH, 56 placebo)
were assigned to receive double-blind therapy. There
were no significant differences observed between the two
treatment groups, except in the patient living situation
at pre-fracture where more placebo-treated patients
came from an independent living situation compared
with hGH-treated patients (96.4 vs 76.4%, P  0:011:
A total of 83 (74.7%) patients completed the first 8
weeks of the study and 76 (68.5%) completed the entire
study period of 24 weeks. The primary reason for
discontinuation during the study was patient decision
(12.6%). Only four (3.6%) patients discontinued due to
an adverse event (three hGH, one placebo), and for
three of these the event was present at study
completion (24 weeks).
Efficacy
No significant differences in the changes in the
Modified Barthel Index score between treatment groups
were observed at any time point during the study (Table
2). However, when the change from baseline to end of
the active treatment phase (8 weeks) for all patients
was analyzed in relation to their age and irrespective of
treatment, it was found that in subjects younger than
75 years little if any change in the Modified Barthel
Index score was observed after the fracture and during
the post-surgical period (Fig. 1), whereas for patients
older than 75 years it showed a more variable recovery.
Accordingly, changes in the Modified Barthel Index
were analyzed in patients younger and older than 75
years of age separately. While no trend emerged in
patients younger than 75 years, the changes from
baseline in the older group were less in the hGH group
than in the placebo group at any time point during the
treatment phase, the difference being greatest after 6
weeks of therapy, with a change in score of 218:6 ^
18 in the hGH group vs 228:1 ^ 26 in the placebo
group P , 0:075; data not shown).
At baseline, the distribution of independent/depen-
dent living situations was different between treatment
groups, being 76.4/23.6% in the hGH group and 96.4/
3.6% in the placebo group (Table 1). Analysis by age
groups showed that this was essentially caused by the
fact that in the hGH group the proportion of subjects
older than 75 years who were in a dependent living
situation was larger than in the placebo group (40.7 vs
8.3%). Because of this uneven baseline distribution,
further analysis of the changes in living situation was
performed by comparing only those patients who were
in an independent living situation at baseline.
The results of this analysis, summarized in Table 3,
show that for all patients again no significant
differences in the distribution of the living situation
Table 1 Summary of demographic characteristics and pre-fracture living situations. Values are no. of patients (%) except where shown as
mean ^ S.D.
All patients n  111 hGH n  55 Placebo n  56 P*
Age (mean ^ S.D.) 78.5^9.1 79.2^8.5 77.8^9.6 0.408
Sex
Female 90 (81.1) 42 (76.4) 48 (85.7) 0.209
Male 21 (18.9) 13 (23.6) 8 (14.3) ±
Barthel Index (mean ^ S.D.) 98.4^3.2 98.3^3.0 98.5^3.6 0.255
Patient living situation
Independent 96 (86.5) 42 (76.4) 54 (96.4) 0.011
House/flat 76 (68.5) 36 (65.5) 40 (71.4) ±
Old people's flat 9 (8.1) 4 (7.3) 5 (8.9) ±
Service flat 11 (9.9) 2 (3.6) 9 (16.1) ±
Dependent 15 (13.5) 13 (23.6) 2 (3.6) ±
Sheltered accommodation 3 (2.7) 3 (5.5) 0 ±
Retirement home/home for the elderly 12 (10.8) 10 (18.2) 2 (3.6) ±
Nursing/convalescent home 0 0 0 ±
Acute hospital 0 0 0 ±
* Pearson chi-square test or one-way ANOVA.
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are apparent throughout the study, although from visit
three to visit six the rate of return to the pre-fracture
independent living situation is higher in the hGH group
than in the placebo group. When patients are split
according to age, no differences between hGH and
placebo are seen for patients ,75 years. After visit six
the percentage of patients in an independent living
situation in the treatment group dropped to 54.4% due
to re-hospitalization of two subjects. However, in
patients older than 75 years the proportion of patients
returning to the pre-fracture living situation over time
was statistically significantly different between treat-
ment groups P  0:034: In the hGH treatment group
no patient was in hospital after visit four and at the end
of the 6 month follow-up period 93.8% were in an
independent and 6.2% in a dependent living situation.
This compares with 75.0 and 25.0% respectively in the
placebo group.
Given the different trends emerging from the above
analysis, the changes in Barthel Index in relation to
living situation and age were investigated. For this
analysis, the changes for both treatment groups in
subjects returning immediately after surgery to an
independent situation were compared with the changes
occurring in patients remaining after fracture in a
dependent living situation. As shown in Fig. 2 there
was no difference in hGH vs placebo for patients in an
independent situation during the 8 weeks, while
patients who were in a dependent living situation
appeared to have higher Barthel Index scores in the
hGH group compared with the placebo group. A formal
analysis of this data was not possible because patients
can move from dependent to independent living during
the course of the study, hence groups shown are not
mutually exclusive.
Baseline IGF-I serum levels for all patients are shown
in Fig. 3. It appears that almost all subjects had IGF-I
serum levels below the 50% percentile for age, some
had values below the 5% percentile. The changes from
baseline (Table 4) showed statistically significant
differences at each time during the active treatment
phase, with the maximum hGH-induced IGF-I increase
observed after 4 weeks. The hGH-stimulated IGF-I
values are in the range of those of normal subjects of
50±60 years of age. Similar and parallel changes were
observed for IGFBP-3 values (data not shown). IGFBP-1
(Table 4) decreased during the study in both hGH- and
placebo-treated patients without any difference
between the treatment groups.
Safety
There were five deaths reported for patients participa-
ting in the study, three in the hGH group and two in the
placebo group. Of the three patients in the hGH group
two died after the end of the active treatment phase.
Only one patient discontinued due to a serious adverse
event during the active phase and this was caused by
ventricular fibrillation, which was not considered to be
related to hGH. The most frequently reported treat-
ment-emergent adverse events were edema (hGH
29.1%, placebo 30.4%), urinary tract infection (hGH
25.5%, placebo 14.3%), and constipation (hGH 16.4%,
placebo 17.9%). There were no statistically significant
differences between the groups for any of the adverse
events.
No statistically significant changes from baseline
were observed for body weight, supine systolic or
diastolic blood pressure and heart rate at any time
during the study. There were no patients discontinu-
ations due to clinical laboratory results and none of the
laboratory abnormalities noted were thought to be
clinically relevant or related to study drug treatment.
There were four patients who had elevated blood
glucose concentration during the study, but none of
these occurrences were considered clinically relevant to
study drug treatment.
Discussion
In the present pilot study we developed a clinical model
to assess the effects of hGH treatment on the clinical
Table 2 Changes from baseline in the modified Barthel Index score
for ADL. n  number of patients with a baseline and at least one
post-baseline measurement in that treatment group.
hGH Placebo
n Mean S.D. Median n Mean S.D. Median P*
Baseline 55 98.2 3.0 100 56 98.5 3.6 100 0.255
Visit (week)
2 (2) 50 237.0 21.0 234.5 50 234.2 23.3 233.5 0.256
3 (4) ± ± ± ± ± ± ± ± ±
4 (6) 42 217.3 16.7 211.5 46 218.7 23.3 27.0 0.465
5 (8) 40 211.8 14.6 27.5 45 213.1 19.3 25.0 0.339
6 (12) 39 27.1 10.0 23.0 44 210.3 20.1 20.5 0.853
7 (24) 36 24.9 11.3 0 43 25.1 14.0 0 0.975
* Two-way ANOVA with main effects for treatment, investigator and the
treatment by investigator interaction.
Figure 1 Difference between baseline (pre-fracture) and endpoint
(8 weeks) in Modified Barthel Index for all patients by age; only
patients with a baseline and a post-baseline measurement are
included (n  100).
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outcome of subjects with accidental hip fractures.
Critical aspects in designing the study were patient
selection criteria, outcome measures, hGH dosage and
duration of treatment, and follow-up period.
The clinical impact of the hip fracture event per se
had to be measurable in order to detect a treatment
effect. Published data indicate that up to 50% of hip
fracture patients do not return to their previous
independent life and living situation (9, 11, 26±28).
Accordingly, only patients living independently at the
time of fracture, as characterized by ADLs and housing
situation were enrolled into the study. Also, other
existing disease entities had to be ruled out both for
safety reasons and to avoid confounding treatment
effects. To assess clinical outcome and possible treat-
ment effects, ADLs and living situation were taken as
measures which best describe the functional and health
status after the hip fracture event. This is supported by
the large amount of data in the literature, which
demonstrate the close relationship that exists in hip
fracture patients between these measures and early as
well as late morbidity and mortality rates. A 6 week
duration of treatment was chosen because the period of
catabolism and of associated functional impairment
after the surgical intervention may be present for
several weeks. However, published data indicate that
the overall clinical outcome 6 months after hip fracture
does not change any further (8, 29, 30), and therefore
a follow-up period of up to 6 months after the primary
accident was considered appropriate for final evalua-
tion.
No overall therapy effect in treatment vs placebo
could be detected by the Barthel Index. However, in
patients younger than 75 years of age there was only
little overall change in the Barthel score, and therefore
clinically relevant treatment effects could not be
detected in this age group. Efficacy analysis by age
Table 3 Distribution in living situation* throughout the study of the patients who had an independent living situation pre-fracture; values are
given as percentages.
Week
Situation Baseline 2 4 6 8 12 24
All patients
hGH (n  27) Independent 100.0 22.2 51.9 55.6 66.7 85.2 77.8
Dependent 0 0 22.2 33.3 29.6 14.8 14.8
Hospital 0 77.8 25.9 11.1 3.7 0 7.4
Placebo (n  43) Independent 100.0 25.6 39.5 46.5 62.8 79.1 86.0
Dependent 0 11.6 32.6 34.9 32.6 18.6 14.0
Hospital 0 62.8 27.9 18.6 4.6 2.3 0
,75 years
hGH (n  11) Independent 100.0 27.3 72.7 72.7 72.7 72.7 54.5
Dependent 0 0 18.2 18.2 18.2 27.3 27.3
Hospital 0 72.7 9.1 9.1 9.1 0 18.2
Placebo (n  19) Independent 100.0 42.1 57.9 63.2 84.2 100 100
Dependent 0 5.3 31.6 31.6 15.8 0 0
Hospital 0 52.6 10.5 5.3 0 0 0
$75 years
hGH (n  16) Independent 100.0 18.8 37.5 43.8 62.5 93.8 93.8
Dependent 0 0 25.0 43.8 37.5 6.2 6.2
Hospital 0 81.3 37.5 12.5 0 0 0
Placebo (n  24) Independent 100.0 12.5 25.0 33.3 45.8 62.5 75.0
Dependent 0 16.7 33.3 37.5 45.8 33.3 25.0
Hospital 0 70.8 41.6 29.2 8.4 4.2 0
* Only includes patients who completed the study through 24 weeks (visit 7). P  0.034 for the proportion of hGH- vs placebo-treated patients .75 years
returning to the independent pre-fracture living situation over time.
Figure 2 Mean score for Modified Barthel Index of ADL for patients
in independent or dependent living situations. The number of
patients within each group varied at each time point since patients
could change from being dependent to independent during the
study.
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significantly reduced the number of patients in each
age group. Also, when living situation was added, the
uneven baseline distribution in independent vs depen-
dent situations in subjects older than 75 further
reduced the power of the analysis. However, the
differences between hGH and placebo observed for
patients older than 75 in rates of return to the previous
independent living situation, as well as the higher
Barthel Index scores observed in the hGH-treated group
not returning to an independent living situation
indicate that the clinical model described in the present
paper has the potential to detect a treatment effect in
favor of hGH in patients older than 75 years of age.
Although not within the anabolic range used in
previous studies (20, 21), the hGH dose of 20 mg/kg
per day was considered appropriate for a pilot study in
an aged patient population. This dose was sufficient to
increase the baseline serum IGF-I concentrations to
values comparable with those of normal subjects of
50±60 years of age. The question, however, remains
whether the IGF-I increase obtained with the hGH dose
used was sufficient to elicit the desired clinical effect.
Low IGF-I values have been reported in hip fracture
subjects (31, 32) and also in our study baseline IGF-I
values were low. These findings suggest that resistance
to GH action, described for catabolic and surgical
trauma patients (33), may also be a feature of patients
with hip fracture. In patients after severe abdominal
surgery it has been demonstrated that a minimal dose
of 60 mg/kg per day is required to prevent a negative
nitrogen balance (34, 35). We therefore speculate that
a higher hGH dose than used in the present study may
produce better clinical efficacy in the study model
used.
Noteworthy, there was little change in serum IGFBP-
1 concentrations and no difference between hGH and
placebo, which is indirect evidence of intact substrate
availability to the hGH action in the studied patient
population, which as a matter of fact represents an
otherwise relatively healthy patient population. By
careful study monitoring, no significant safety issue
emerged in this study. This is important as Takala and
co-workers (36) recently reported the results of two
studies on the effect of high doses of GH on the outcome
in critically ill adults who were hospitalized for long
periods. These two placebo-controlled trials in parallel
involved 247 Finnish patients and 285 patients in
other European countries who had been in an intensive
care unit for 5 to 7 days and who were expected to
require intensive care for at least 10 days. These
patients received either GH 0:10 ^ 0:02 mg=kg per
day) or placebo until discharge from intensive care or
for a maximum of 21 days. These investigators found
that the relative risk of death for patients receiving GH
was 1.9 in the Finnish study and 2.4 in the multi-
national study (36). At the time of enrolment, patients
in our study were more or less healthy, except for the
accidental hip fracture, which is possibly the explana-
tion for the fact that no safety issues did emerge.
Subjects with accompanying diseases excluded from
the study would a priori not have benefited from an
Figure 3 Baseline serum IGF-I concentrations in patients with
acute accidental hip fracture. (W) females, (X) males. The normal
range is given by the 5th, 50th and 95th percentile.
Table 4 Changes from baseline in serum IGF-I and IGFBP-1 concentrations (mg/l). n  number of patients with a baseline and at least
one post-baseline measurement in that treatment group.
hGH Placebo
n Mean S.D. Median n Mean S.D. Median P*
IGF-I baseline level 53 79.9 33.8 68.0 56 77.5 28.4 77.5 0.715
Change at week
2 12 53.9 29.1 56.5 13 22.5 25.7 2.0 ,0.001
4 46 102.0 68.9 102.5 47 8.8 26.9 8.0 ,0.001
8 40 18.4 28.6 14.0 44 10.6 24.9 10.5 0.397
Endpoint (0±8) 47 26.4 40.3 15.0 48 10.5 24.1 11.0 0.105
IGFBP-1 baseline level 53 46.5 43.0 34.8 56 48.0 40.9 36.8 0.788
Change at week
2 12 228.8 49.7 28.9 13 20.9 49.0 10.5 0.104
4 46 217.6 39.7 24.6 47 218.8 37.2 27.1 0.811
8 40 219.0 42.5 26.9 44 219.8 40.3 28.3 0.920
Endpoint (0±8) 44 219.7 40.7 29.0 48 217.5 41.0 28.3 0.445
* Two-way ANOVA performed on rank-transformed data.
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hGH therapy or met contraindications already valid for
GH deficiency replacement therapy.
In summary, hGH treatment with a dose of 20 mg/kg
per day, started pre- (peri-)operatively and given for a
period of 6 weeks to patients with an accidental hip
fracture results in a significant increase in serum IGF-I
and IGFBP-3 to levels comparable with mean concen-
trations in healthy subject of 50±60 years of age.
Furthermore while no differences in treatment vs
placebo were observed in ADL scores, in subjects
older than 75 years a significant increase in the rate
of return to the pre-fracture living situation was
observed compared with placebo.
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